Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival (Q48429078)
Jump to navigation
Jump to search
scientific article published on 6 September 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival |
scientific article published on 6 September 2013 |
Statements
1 reference
Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival (English)
1 reference
Loukas Settas
1 reference
Irini Flouri
1 reference
Theodora E Markatseli
1 reference
Paraskevi V Voulgari
1 reference
Kyriaki A Boki
1 reference
Ioannis Papadopoulos
1 reference
Dimitrios Zisopoulos
1 reference
Fotini N Skopouli
1 reference
Alexios Iliopoulos
1 reference
George K Bertsias
1 reference
Pierre Geborek
1 reference
Alexandros A Drosos
1 reference
Dimitrios T Boumpas
1 reference
Prodromos Sidiropoulos
1 reference
6 September 2013
1 reference
43
1 reference
4
1 reference
447-457
1 reference
Identifiers
1 reference